8-K: Rani Therapeutics Faces Nasdaq Delisting Threat Over Minimum Bid Price Non-Compliance

Rani Therapeutics Holdings, Inc. has received a notice from Nasdaq regarding non-compliance with the minimum bid price requirement, potentially leading to delisting if not rectified by December 17, 2025.

Summary

• Rani Therapeutics Holdings, Inc. (Company) received a notice from Nasdaq on June 20, 2025, indicating non-compliance with the minimum bid price requirement for continued listing.
• The Company's Class A common stock's closing bid price for the prior 30 consecutive business days fell below the $1.00 per share minimum required by Nasdaq Listing Rule 5450(a)(1).
• Under Nasdaq Listing Rule 5810(c)(3)(A), Rani Therapeutics has a 180-day compliance period, ending on December 17, 2025, to regain compliance.
• To regain compliance, the Company's common stock must achieve and maintain a minimum bid price of at least $1.00 per share for a minimum of 10 consecutive business days.
• If compliance is not regained by December 17, 2025, the Company may be eligible for an additional 180-calendar day compliance period if it transfers to The Nasdaq Capital Market.
• Eligibility for the second compliance period requires meeting continued listing requirements for market value of publicly held shares and all other initial listing standards (except the bid price), and providing written notice of intent to cure, potentially via a reverse stock split.
• Failure to regain compliance within the specified periods, including any extensions, will result in the delisting of the Common Stock.

Sentiment

Score: 2

Explanation: The document conveys highly negative news regarding the company's stock performance and its continued listing on Nasdaq, indicating a significant risk of delisting.

Negatives

• The Company's Class A common stock has failed to maintain the minimum $1.00 bid price requirement for continued listing on The Nasdaq Global Market.
• Rani Therapeutics is at risk of delisting from Nasdaq if it cannot regain compliance within the specified periods.
• The notice highlights significant underperformance of the Company's stock price.

Risks

• The primary risk is the potential delisting of Rani Therapeutics' Class A common stock from The Nasdaq Global Market.
• There is no assurance that the Company will be able to regain compliance with the minimum bid price requirement.
• There is no assurance that Nasdaq will grant the Company a further extension of time to regain compliance, if applicable.
• Failure to regain compliance could lead to reduced liquidity and investor confidence in the Company's stock.

Future Outlook

The Company intends to monitor the closing bid price of its Common Stock and consider available options to resolve the noncompliance with the Minimum Bid Price Requirement. However, there is no assurance that the Company will be able to regain compliance or receive a further extension from Nasdaq.

Management Comments

• "The Company intends to monitor the closing bid price of the Common Stock and consider its available options to resolve the noncompliance with the Minimum Bid Price Requirement."

Industry Context

This announcement reflects a common challenge faced by smaller or emerging growth companies, particularly in the biotechnology sector, where stock performance can be volatile and susceptible to market sentiment or clinical trial outcomes. Maintaining listing standards is crucial for liquidity and investor access, and non-compliance can signal underlying operational or market perception issues.

Stakeholder Impact

• Shareholders face the risk of reduced liquidity and potential loss of value if the stock is delisted from Nasdaq.
• The Company's ability to raise capital in the future may be negatively impacted by a potential delisting.
• Employee morale and retention could be affected by the uncertainty surrounding the Company's stock listing.

Next Steps

• Rani Therapeutics will monitor the closing bid price of its Common Stock.
• The Company will consider available options to resolve the noncompliance with the Minimum Bid Price Requirement.
• If compliance is not regained, the Company may seek to transfer to The Nasdaq Capital Market for an additional compliance period, potentially involving a reverse stock split.

Key Dates

Recommendation

Keywords

Rani Therapeutics, Nasdaq, Delisting, Minimum Bid Price, Stock Compliance, 8-K Filing, Corporate Governance, Publicly Traded, Biotechnology